Daniel O'Connell M.D.

Daniel O'Connell MD, PhD is an experienced professional in the biotech and investment sectors, currently serving as a Board Member at Terremoto Biosciences since November 2023 and a Partner at Novo Holdings since June 2022. Previously, O'Connell held positions including Executive Director of Equity and Venture Capital at Bristol Myers Squibb, where guidance was provided for strategic therapeutic opportunities, and a Board Member at multiple companies such as Link Immunotherapeutics, LogicBio Therapeutics, and PreciThera, impacting various innovative therapeutic developments. O'Connell's background includes investment roles at Arix Bioscience and private equity at OrbiMed Advisors, as well as a solid educational foundation with an MD/PhD from Tufts University School of Medicine and a degree in Mathematics and Chemistry from the Massachusetts Institute of Technology.